These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15184306)

  • 21. [Gefitinib in non-small cell lung cancer].
    Nakagawa K
    Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
    [No Abstract]   [Full Text] [Related]  

  • 22. Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
    William WN; Gold KA; Kim ES
    Ann Oncol; 2009 Sep; 20(9):1455-1457. PubMed ID: 19704160
    [No Abstract]   [Full Text] [Related]  

  • 23. [Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
    Lv P; Zhou T
    Zhongguo Fei Ai Za Zhi; 2010 Mar; 13(3):247-53. PubMed ID: 20673523
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
    Dancey JE
    Cancer Cell; 2004 May; 5(5):411-5. PubMed ID: 15144948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
    Ranson M; Thatcher N
    Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
    [No Abstract]   [Full Text] [Related]  

  • 26. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
    Jackman DM; Holmes AJ; Lindeman N; Wen PY; Kesari S; Borras AM; Bailey C; de Jong F; Jänne PA; Johnson BE
    J Clin Oncol; 2006 Sep; 24(27):4517-20. PubMed ID: 16983123
    [No Abstract]   [Full Text] [Related]  

  • 27. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
    Dahlberg SE; Gray RJ; Johnson BE
    J Clin Oncol; 2008 Sep; 26(26):4233-5. PubMed ID: 18779608
    [No Abstract]   [Full Text] [Related]  

  • 28. Gefitinib maintenance in stage III non-small-cell lung cancer.
    Stewart DJ
    J Clin Oncol; 2008 Oct; 26(29):4849-50; author reply 4850-1. PubMed ID: 18779595
    [No Abstract]   [Full Text] [Related]  

  • 29. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
    Kakiuchi S; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
    [No Abstract]   [Full Text] [Related]  

  • 30. Medicine. Why a new cancer drug works well, in some patients.
    Marx J
    Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
    [No Abstract]   [Full Text] [Related]  

  • 31. Hair growth after gefitinib treatment.
    Lee LW; Burt PA
    Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):492-3. PubMed ID: 16149296
    [No Abstract]   [Full Text] [Related]  

  • 32. Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
    Sharma A; Tan TH; Cheetham G; Scott HS; Brown MP
    J Thorac Oncol; 2012 May; 7(5):941-2. PubMed ID: 22722798
    [No Abstract]   [Full Text] [Related]  

  • 33. [Iressa (gefitinib)].
    Kudoh S; Yoshimura A; Gemma A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib Approved for EGFR-Mutated NSCLC.
    Cancer Discov; 2015 Sep; 5(9):896. PubMed ID: 26238462
    [No Abstract]   [Full Text] [Related]  

  • 35. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
    Kim YH; Mio T; Mishima M
    Intern Med; 2009; 48(18):1677-9. PubMed ID: 19755773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
    [No Abstract]   [Full Text] [Related]  

  • 37. KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
    Ohara G; Kurishima K; Ishikawa H; Satoh H; Hizawa N
    Lung Cancer; 2008 Jan; 59(1):138; author reply 139. PubMed ID: 18006181
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictors of clinical response of non-small cell cancer to gefitinib.
    Ardizzoni A; Tiseo M
    JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
    [No Abstract]   [Full Text] [Related]  

  • 39. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 40. Gefitinib versus docetaxel for previously treated NSCLC--letter.
    Tassinari D; Lazzari-Agli L; Tombesi P; Sartori S
    Clin Cancer Res; 2011 Jul; 17(13):4610; author reply 4611. PubMed ID: 21712456
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.